$26.45
-0.03-0.09%
Last update: 11:53 AM
15 minutes delayed
Comments
Loading...
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Stock, Analyst Ratings, Price Targets, Forecasts
Kiniksa Pharmaceuticals International PLC has a consensus price target of $32.33 based on the ratings of 6 analysts. The high is $34 issued by Wedbush on July 23, 2024. The low is $30 issued by JP Morgan on May 1, 2024. The 3 most-recent analyst ratings were released by Wedbush, Wells Fargo, and JP Morgan on July 23, 2024, May 3, 2024, and May 1, 2024, respectively. With an average price target of $32.67 between Wedbush, Wells Fargo, and JP Morgan, there's an implied 23.48% upside for Kiniksa Pharmaceuticals International PLC from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
Wells Fargo
JP Morgan
Evercore ISI Group
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for Kiniksa Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/23/2024 | Buy Now | 28.52% | Wedbush | David Nierengarten | $30 → $34 | Maintains | Outperform | Get Alert |
| 05/03/2024 | Buy Now | 28.52% | Wells Fargo | Eva Fortea Verdejo | → $34 | Initiates | → Overweight | Get Alert |
| 05/01/2024 | Buy Now | 13.4% | JP Morgan | Anupam Rama | $26 → $30 | Maintains | Overweight | Get Alert |
| 04/24/2024 | Buy Now | 13.4% | Evercore ISI Group | Liisa Bayko | $25 → $30 | Maintains | Outperform | Get Alert |
| 01/02/2024 | Buy Now | -5.5% | Wedbush | David Nierengarten | $23 → $25 | Maintains | Outperform | Get Alert |
| 07/26/2023 | Buy Now | 20.96% | Goldman Sachs | Paul Choi | $22 → $32 | Maintains | Buy | Get Alert |
| 03/09/2023 | Buy Now | -24.4% | JP Morgan | Anupam Rama | $19 → $20 | Maintains | Overweight | Get Alert |
| 12/29/2021 | Buy Now | 28.52% | B of A Securities | Geoff Meacham | $37 → $34 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Kiniksa Pharmaceuticals (KNSA) stock?
The latest price target for Kiniksa Pharmaceuticals (NASDAQ:KNSA) was reported by Wedbush on July 23, 2024. The analyst firm set a price target for $34.00 expecting KNSA to rise to within 12 months (a possible 28.52% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kiniksa Pharmaceuticals (KNSA)?
The latest analyst rating for Kiniksa Pharmaceuticals (NASDAQ:KNSA) was provided by Wedbush, and Kiniksa Pharmaceuticals maintained their outperform rating.
When was the last upgrade for Kiniksa Pharmaceuticals (KNSA)?
There is no last upgrade for Kiniksa Pharmaceuticals
When was the last downgrade for Kiniksa Pharmaceuticals (KNSA)?
There is no last downgrade for Kiniksa Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Kiniksa Pharmaceuticals (KNSA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kiniksa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kiniksa Pharmaceuticals was filed on July 23, 2024 so you should expect the next rating to be made available sometime around July 23, 2025.
Is the Analyst Rating Kiniksa Pharmaceuticals (KNSA) correct?
While ratings are subjective and will change, the latest Kiniksa Pharmaceuticals (KNSA) rating was a maintained with a price target of $30.00 to $34.00. The current price Kiniksa Pharmaceuticals (KNSA) is trading at is $26.46, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.